TY  - GEN
AU  - Lepretre,Stephane
AU  - Aurran,Therese
AU  - Mahé,Beatrice
AU  - Cazin,Bruno
AU  - Tournilhac,Olivier
AU  - Maisonneuve,Herve
AU  - Casasnovas,Olivier
AU  - Delmer,Alain
AU  - Leblond,Veronique
AU  - Royer,Bruno
AU  - Corront,Bernadette
AU  - Chevret,Sylvie
AU  - Delépine,Roselyne
AU  - Vaudaux,Sandrine
AU  - Van Den Neste,Eric
AU  - Béné,Marie Christine
AU  - Letestu,Remi
AU  - Cymbalista,Florence
AU  - Feugier,Pierre
TI  - Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial
SN  - 1528-0020
PY  - 2012///0730
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cyclophosphamide
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Rituximab
KW  - Survival Rate
KW  - Time Factors
KW  - Vidarabine
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2011-07-365437
ER  -